The Medicines Company - Product Pipeline Review - 2016
Global Markets Direct’s, ‘The Medicines Company - Product Pipeline Review - 2016’, provides an overview of the The Medicines Company’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by The Medicines Company, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
- The report provides a snapshot of the pipeline therapeutic landscape of The Medicines Company - The report provides overview of The Medicines Company including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses The Medicines Company’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features The Medicines Company’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate The Medicines Company’s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for The Medicines Company - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding The Medicines Company’s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
75 pages •
By Wright Investors' Service
• Sep 2018
A textual analysis of the financial results for United Therapeutics Corporation compared to selected competitors. Also included are quantitative analyses of the company's financial statements, extensive ratio analyses and up to 10-year history of sales, earnings, dividends and security pricing. A business description of the company, including...
Summary Merrimack Pharmaceuticals Inc (Merrimack) is a clinical stage biopharmaceutical company that develops and commercializes medicines for the treatment of various types of cancers.The company’s marketed portfolio consists of Onivyde (irinotecan liposome injection) that encases irinotecan (marketed chemotherapy drug)...
Summary Aviragen Therapeutics Inc (Aviragen) is a pharmaceutical company that carries out anti-infective drug discovery, development and its commercialization to treat respiratory diseases.It has four product candidates in clinical development which address viral infections, namely, vapendavir, oral broad spectrum capsid...
Summary Cesca Therapeutics Inc (Cesca) researches, develops, and commercializes cell based therapeutics for applications in regenerative medicine.Its proprietary technology platform, PXP is used to develop autologous cell-based therapies for the in the vascular and orthopedic markets. Its device division, ThermoGenesis...
Summary Navidea Biopharmaceuticals Inc (Navidea) is a biopharmaceutical company that develops precision immunodiagnostic agents and immunotherapeutics.. The company is focused on developing multiple precision-targeted products based on its Manocept platform to improve patient care. Its pipeline products include MT-1002;...
Summary Astellas Pharma Inc (Astellas) is one of the leading global pharmaceutical companies, which focuses on the research, development, manufacture and commercialization of a wide range of pharmaceuticals.The company’s product portfolio comprises both marketed and pipeline products for the treatment of a wide range of...